Abstract:Female gender, contraceptives, and menopausal hormone replacement treatments containing progesterone analogues associate with higher risk of meningiomas yet with lower risk of gliomas. Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. However, much less is known in regard to progesterone actions in gliomas despite PR expression strongly correlates with their grade. Meningiomas and gliomas may grow faster during gestation; but paradoxically, parousity reduces lifetime risk of gliomas which can be explained with dichotomous cell growth-stimulating and inhibitory actions of progesterone at low versus high levels. Progesterone levels gradually increase in gestation up to 200-fold and the incidence of highly angiogenic brain tumors decreases in the last trimester. Indeed, progesterone stimulates glial tumor cell growth at low doses (10 nM) while induces cell kill at higher doses. During gestation, some immune pathways are activated to protect the mother and the fetus against microbial pathogens. In parallel, high-dose medroxyprogesterone acetate (MPA) used in treatment of endometrial carcinoma decreases tumoral expression of PR-B and increases infiltration of cytotoxic T lymphocytes and natural killer cells. MPA also synergies with IL-2 in clinical treatment of renal cancer. In both glioma and meningioma, the dominant cytosolic PR is PR-B which increases cell growth, while PR-A limits cell growth. This seems also paradoxical at the first glance due to opposite behavior of these tumors in diverse endocrine conditions. High-dose progestins may inhibit brain tumor growth by downregulating PR-B, yet the dosage thresholds may differ between glial and meningeal tumors due to higher total PR expression in meningiomas. Supporting this proposal, certain progestins were reported to stimulate meningioma growth in anecdotal reports, but same agents at much higher doses reduced meningioma cell proliferation in pilot clinical studies. PR antagonist mifepristone reduced meningioma growth in some clinical studies, but lacked efficacy in others. In fact, mifepristone also has partial PR agonist efficacy and acts in synergy with MPA to block EC growth. Hence, a similar mechanism of receptor downregulation may also account for mifepristone. Both MPA and mifepristone also harbor myeloprotective features against chemotherapy. Ulipristal is another contraceptive PR antagonist and exerts promising anticancer activity on drug-resistant ovarian cancer and BRCA1-mutant breast cancer cells, which can be tested in animal glioblastoma models. We propose that progestins strongly deserve to be investigated in experimental models of glioblastoma alone and in combination with immunostimulating agents.

The prognostic impact of Progesteron-receptor expression in surgical intracranial meningioma on performance status and quality of life. A single-center observational study

Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.

Ncmp-03. Association Of Progesterone Contraception With Tumor-Related Visual Impairment In Premenopausal Women With Meningioma Referred For Radiation

Progesterone Receptor Expression and Prediction of Benefits of Adjuvant Radiotherapy in De Novo Atypical Meningiomas after Gross-Total Resection.

Uncovering the molecular landscape of meningiomas and the impact of perioperative steroids on patient survival

Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma

A Multivariate Analysis of the Prognostic Factors of Grade III Gliomas

Retrospective and Randomized Analysis of Influence and Correlation of Clinical and Molecular Prognostic Factors in a Mono-Operative Series of 122 Patients with Glioblastoma Treated with STR or GTR

Prognostic factors for patients with glioma located in brain eloquent areas

Positive Progesterone Receptor Expression in Meningioma May Increase the Transverse Relaxation: First Prospective Clinical Trial Using Single-Shot Ultrafast T 2 Mapping

Surveillance, Epidemiology, and End Results database and propensity score matching analysis of postoperative radiotherapy for non malignant meningioma: A retrospective cohort study

Prediction of Meningioma Grade Using Hematological Parameters

Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse

1245 Malignant Meningioma Survival, Recurrence and Functional Outcomes in an International Multicenter Cohort

Postoperative peritumoral edema is correlated with the prognosis in intracranial meningioma with preoperative peritumoral edema

Analysis of Prognostic Factors of World Health Organization Grade III Meningiomas

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma

A Clinical Prognostic Model Based on Preoperative Hematological and Clinical Parameters Predicts the Progression of Primary WHO Grade II Meningioma

Clinical and Prognostic Features of Spinal Meningioma: a Thorough Analysis from a Single Neurosurgical Center.

Prognostic factors and long-term outcomes of primary intracranial rhabdoid meningioma: A systematic review

Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study